Ericsson Supports Global Health Innovation Network in Singapore
Ericsson Supports Global Health Innovation Network in Singapore
The partnership was formalised through the signing of a Memorandum of Understanding (MoU) at the Singapore-Sweden Royal Business Forum, witnessed by State Secretary for Healthcare, Ms Miriam Söderström and Singapore's Permanent Secretary for Policy and Development, Ms Lai Wei Lin. The event was attended by Singapore's Minister for Health, Mr Ong Ye Kung.
該合作關係通過在新加坡-瑞典皇家商業論壇上籤署諒解備忘錄（MoU）形式化，見證人包括衛生國務秘書米莉亞姆·索德斯特倫和新加坡政策與發展常秘書賴維琳。此次活動由新加坡衛生部長王乙康出席。
GHIN will identify, implement, and scale health innovations in screening, diagnosis, and monitoring. The purpose of the GHIN is to facilitate the actual implementation of innovative technology, which is the major challenge globally in driving healthcare innovation forward.
GHIN將識別、實施和擴展篩查、診斷和監測領域的健康創新。GHIN的目的是促進創新技術的實際實施，這是全球推動醫療創新向前發展的主要挑戰。
This collaboration marks the first concrete initiative under the government-to-government MoU on healthcare innovation collaboration, signed by Singapore and Sweden during the same event.
此次合作標誌着在新加坡與瑞典於同一活動上籤署的政府間醫療創新合作諒解備忘錄下的首個具體舉措。
Scaling innovations and sharing expertise
擴展創新與分享專業知識
The GHIN brings together various players in the healthcare, pharmaceutical and communication industries. NUHS and Sahlgrenska University Hospital will take on a shared role of providing clinical experience and knowledge, hospital resources for prototype testing and research, sharing research materials and publications as well as providing mentoring support. By leveraging their collective expertise, all the partners will work towards facilitating the development of novel technologies in healthcare, successful implementation and scaling up of these healthcare services.
GHIN匯聚了醫療、藥品和通訊行業的各方參與者。NUHS和薩爾格倫斯卡大學醫院將共同承擔提供臨床經驗和知識、醫院資源用於原型測試和研究、分享研究材料和出版物以及提供指導支持的角色。通過利用他們的集體專業知識，所有合作伙伴將共同努力促進醫療領域新技術的發展，以及這些醫療服務的成功實施和擴展。
"Implementing the newest technologies and leveraging opportunities from research and innovation worldwide strengthens global healthcare," states Dr Boubou Hallberg, CEO, Sahlgrenska University Hospital. "This collaboration also helps new treatments reach patients from all over the world faster."
「實施最新技術並利用全球研究和創新的機會，將加強全球醫療，」薩爾格倫斯卡大學醫院首席執行官鮑布·霍爾貝格博士表示。「此合作還幫助新的治療方法更快地到達來自全球各地的患者。」
"As an academic health system, we will bring together expertise in clinical care, research, and education to support this collaboration," states Adjunct Professor Jason Phua, Deputy Chief Executive (Clinical Transformation), NUHS.
「作爲一個學術健康系統，我們將彙集臨床護理、研究和教育方面的專業知識來支持這一合作，」NUHS臨床轉型副首席執行官助理教授賈森·普阿表示。
"When we combine our strengths with the unique capabilities of our partners, we can contribute meaningfully to the advancement of patient care and the improvement of global health."
「當我們將自身的優勢與合作伙伴獨特的能力結合在一起時，我們可以爲提升患者護理和改善全球健康作出有意義的貢獻。」
Ms Kim Suyeon, Country President, AstraZeneca Singapore says, "We are really excited to come onboard this meaningful collaboration, leveraging AstraZeneca's global healthcare innovation platform, A.Catalyst Network. As part of a broader network of ecosystem stakeholders, our role as a founding industry partner is to support the scouting of innovative solutions towards solving identified problem statements across the healthcare systems, potentially helping to scale effectively implemented solutions to other markets via our network."
阿斯利康新加坡的國家總裁金瑞妍女士表示："我們非常期待參與這項有意義的合作，利用阿斯利康的全球醫療創新平台A.Catalyst Network。作爲生態系統利益相關者更廣泛網絡的一部分，我們作爲創始行業合作伙伴的角色是支持尋找創新解決方案，以解決醫療系統中識別出的問題，同時可能有助於將有效實施的解決方案推廣到我們網絡中的其他市場。"
"High performance connectivity based on 5G will transform healthcare. By joining the GHIN as a founding partner, we will fuel innovation in healthcare services based on our ability to blend technological innovation with medical knowledge. With 5G, we can extend the reach of the healthcare system to many people for whom healthcare access and treatment is a challenge." says Mr Daniel Ode, Head of Ericsson Singapore, Philippines and Brunei.
"基於5G的高性能連接將會改變醫療服務。作爲GHIN的創始合作伙伴，我們將促進醫療服務的創新，因爲我們能夠將科技創新與醫療知識相結合。有了5G，我們可以將醫療系統的覆蓋面擴展到許多面臨醫療接入和治療挑戰的人。" 新加坡、菲律賓和文萊愛立信負責人丹尼爾·奧德先生說道。
Business Sweden will serve as the project management office (PMO) for GHIN, facilitating collaboration and strengthening connections between Swedish, Singaporean, and international stakeholders.
瑞典商業局將作爲GHIN的項目管理辦公室（PMO），促進瑞典、新加坡和國際利益相關者之間的合作並加強聯繫。
"I am proud that Business Sweden can support GHIN and hope that we can enable a strong and productive collaboration. We will focus on expanding its reach by bringing in new partners and aim for faster adoption and larger scaling of healthcare innovations worldwide."
"我很自豪瑞典商業局能夠支持GHIN，並希望我們能夠推動強大而富有成效的合作。我們將專注於通過引入新合作伙伴來擴大其覆蓋面，並致力於更快的採納和更大規模的全球醫療創新。"
GHIN has been created as an open innovation ecosystem, welcoming collaborations with Swedish, Singaporean, and international stakeholders. While the establishment of the GHIN is still in the early stages, the founding members hope that more partners will come onboard in the years ahead, to amplify their collective efforts in creating more effective healthcare solutions globally.
GHIN作爲一個開放的創新生態系統而建立，歡迎與瑞典、新加坡和國際利益相關者的合作。儘管GHIN的成立仍處於早期階段，創始成員希望在未來的幾年內能夠有更多合作伙伴加入，以增強他們在創造更有效的全球醫療解決方案方面的集體努力。
NOTES TO EDITORS:
編輯注：
FOLLOW US:
關注我們：
Subscribe to Ericsson press releases here
Subscribe to Ericsson blog posts here
在此訂閱愛立信新聞稿
在此訂閱愛立信博客文章
MORE INFORMATION AT:
Ericsson Newsroom
media.relations@ericsson.com (+46 10 719 69 92)
investor.relations@ericsson.com (+46 10 719 00 00)
了解更多信息，請訪問：
愛立信新聞室
media.relations@ericsson.com (+46 10 719 69 92)
investor.relations@ericsson.com (+46 10 719 00 00)
ABOUT ERICSSON:
關於愛立信：
Ericsson's high-performing networks provide connectivity for billions of people every day. For nearly 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality.
愛立信的高效網絡爲每天的數十億人提供連接。近150年來，我們一直致力於創建通信技術。我們爲服務提供商和企業提供移動通信和連接解決方案。與客戶和合作夥伴一起，我們將明日數字世界變爲現實。
ABOUT THE NATIONAL UNIVERSITY HEALTH SYSTEM (NUHS)
關於國立大學健康系統（NUHS）
The National University Health System (NUHS) aims to transform how illness is prevented and managed by discovering causes of disease, development of more effective treatments through collaborative multidisciplinary research and clinical trials, and creation of better technologies and care delivery systems in partnership with others who share the same values and vision.
國家大學健康系統（NUHS）的目標是通過發現疾病的原因、通過跨學科的協作研究和臨床試驗開發更有效的治療方法，以及與共享相同價值觀和願景的其他合作伙伴共同創建更好的技術和護理交付系統，來改進疾病的預防和管理。
Institutions in the NUHS Group include the National University Hospital, Ng Teng Fong General Hospital, Jurong Community Hospital and Alexandra Hospital; three National Specialty Centres - National University Cancer Institute, Singapore (NCIS), National University Heart Centre, Singapore (NUHCS) and National University Centre for Oral Health, Singapore (NUCOHS); the National University Polyclinics (NUP); Jurong Medical Centre; and three NUS health sciences schools – NUS Yong Loo Lin School of Medicine (including the Alice Lee Centre for Nursing Studies), NUS Faculty of Dentistry and NUS Saw Swee Hock School of Public Health.
NUHS集團的機構包括國家大學醫院、黃廷芳綜合醫院、裕廊社區醫院和亞歷山大醫院；三個國家專業中心——新加坡國家大學癌症研究所（NCIS）、新加坡國家大學心臟中心（NUHCS）和新加坡國家大學口腔健康中心（NUCOHS）；國家大學門診（NUP）；裕廊醫療中心；以及三所NUS健康科學學院——NUS楊璐琳醫學院（包括愛麗絲李護理研究中心）、NUS牙科學院和NUS蘇瑞霍公共衛生學院。
With member institutions under a common governance structure, NUHS creates synergies for the advancement of health by integrating patient care, health science education and biomedical research.
在共同行政架構下，NUHS通過整合病人護理、健康科學教育和生物醫藥研究，爲健康的推進創造協同效應。
As a Regional Health System, NUHS works closely with health and social care partners across Singapore to develop and implement programmes that contribute to a healthy and engaged population in the Western part of Singapore.
作爲一個區域型健康系統，NUHS與新加坡各地的健康和社會護理合作伙伴密切合作，開發和實施有助於新加坡西部地區健康和積極參與人口的項目。
For more information, please visit .
更多資訊，請訪問。
ABOUT ASTRAZENECA
關於阿斯利康
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
阿斯利康（LSE/STO/納斯達克：AZN）是一家全球性的、以科學爲主導的藥品公司，專注於腫瘤學、罕見疾病和生物醫藥等領域的處方藥的發現、開發和商業化，包括心血管、腎臟與代謝，以及呼吸與免疫學。阿斯利康總部位於英國劍橋，其創新藥物在125多個國家銷售，全球數百萬患者使用。請訪問astrazeneca.com，並在社交媒體上關注公司@AstraZeneca。
